Our Mission: We create, develop, acquire, manufacture, and market products that improve people’s lives.

Our Vision: To make a meaningful difference in the lives of people we serve.

Aerie Pharmaceuticals is a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases.

• Aerie Pharmaceuticals, Inc. is a publicly traded company (NASDAQ: AERI)
• Offices
  • Headquarters – Durham, NC
  • Irvine, CA
  • Bedminster, NJ
  • Dublin, Ireland
  • Tokyo, Japan
• Manufacturing Facilities
  • Athlone, Ireland (cGMP sterile fill plant)
  • Durham, NC (cGMP PRINT® implant production laboratory)
• Employees: Approximately 400

• Rhopressa^® (netarsudil ophthalmic solution) 0.02%
  • U.S. FDA approval – December 2017
  • U.S. commercial launch – April 2018
• Rocklatan^® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%
  • U.S. FDA approval – March 2019
  • U.S. commercial launch – May 2019
• Rhokiinsa^® (netarsudil 200 micrograms/ml eye drops solution)
  • EU marketing authorisation – November 2019
• Roclanda^® (netarsudil 200 micrograms/ml and latanoprost 50 micrograms/ml eye drops)
  • EU marketing authorisation – January 2021
  • Mercury 3 90-day topline results announced
  • Marketing authorisation for Great Britain – April 2021

• Globalization plan for netarsudil franchise underway
  • Europe
    • Exclusive license agreement completed with Santen for Europe and several other regions
  • Japan
    • Phase 2 study of netarsudil completed
    • Exclusive collaboration and license agreement completed with Santen for Japan and 8 other Asian nations.
    • Positive Phase 3 topline results reported October 2021
• Dry Eye Disease program
  • AR-15512 (TRPM8 receptor agonist eye drop)
    • Phase 2b trial (COMET-1) results reported September 2021
    • Phase 3 trials (COMET-2 & COMET-3) underway
• Retinal Disease program
  • AR-1105 (dexamethasone sustained release implant)
    • Positive Phase 2 topline results reported July 2020
    • Phase 3 planning underway in the U.S. and EU
  • AR-13503 (Rho kinase/Protein kinase C inhibitor sustained release implant)
    • First-in-human clinical study ongoing
  • AR-14034 (Pan-VEGF receptor inhibitor sustained release implant)
    • IND-enabling pre-clinical studies underway
• Small-molecule multi-kinase inhibitors in discovery and pre-clinical development for other ophthalmic diseases and conditions
  • Proprietary library of more than 4,000 molecules